Finerenone in Type 1 Diabetes and Chronic Kidney Disease
New England Journal of Medicine · 04.06.2026 · 394 (21) · 2170-2172
DOI: 10.1056/nejmc2604395 ↗Kurz gefasst
Leserbrief in der Zeitschrift New England Journal of Medicine, erschienen am 04.06.2026. Verfasst von Muhammad Aaqib Shamim und 2 weiteren Autor:innen. Beteiligte Einrichtung: All India Institute of Medical Sciences, Jodhpur. Die Arbeit nennt 10 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
To the Editor: The trial by Heerspink et al. (March 5 issue) 1 yields an important finding — finerenone reduced albuminuria in patients with type 1 diabetes. The exclusion of patients receiving sodium–glucose cotransporter 2 (SGLT2) inhibitors or glucagon-like peptide-1 (GLP-1) receptor agonists renders uncertain the incremental benefit of finerenone over contemporary renoprotective therapies 2 and leaves the question of real-world usefulness unanswered. Although participants had to have a serum potassium level of 4.8 mmol per liter or less at screening, Figure 2 in the article indicates that approximately a quarter of the participants had a level of more than 4.8 mmol . . .
Autor:innen und Institutionen
- All India Institute of Medical Sciences, Jodhpur.
Zitieren
APA
Shamim, M. A., Varthya, S. B., & Singh, S. (2026). Finerenone in Type 1 Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 394(21), 2170-2172. https://doi.org/10.1056/nejmc2604395
Vancouver
Shamim MA, Varthya SB, Singh S. Finerenone in Type 1 Diabetes and Chronic Kidney Disease. New England Journal of Medicine. 2026;394(21):2170-2172. doi:10.1056/nejmc2604395
BibTeX
@article{Shamim2026,
author = {Shamim, Muhammad Aaqib and Varthya, Shoban Babu and Singh, Surjit},
title = {Finerenone in Type 1 Diabetes and Chronic Kidney Disease},
journal = {New England Journal of Medicine},
year = {2026},
volume = {394},
number = {21},
pages = {2170--2172},
doi = {10.1056/nejmc2604395}
}
EUVIMED